Company intelligence / Profile preview

LipoMedix

Ownership: Private
Development stage: Phase 2

Overview

LipoMedix has developed Promitil®, a pegylated liposomal formulation of a mitomycin-c lipidic prodrug. This approach enables selective tumor targeting with reduced toxicity compared to conventional mitomycin-c. Promitil® has shown activity against various cancers in animal models and has advanced to Phase II clinical trials for colorectal and other solid tumors. The company’s technology aims to overcome the limitations of traditional chemotherapy by improving efficacy and safety through targeted delivery.

Therapeutic areas: Oncology
Modalities: Small molecules (liposomal prodrugs)Liposome-based drug delivery
Industry: Biotech

Drug pipeline

3 assets

Mitomycin-c lipidic prodrug

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on LipoMedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LipoMedix.

Explore the full profile